Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

391 questions · 443 findings · 71 reviews

No studies found 54 · 12.2%GRADE not reported 105 · 23.7%Very low 125 · 28.2%Low 103 · 23.3%Moderate 40 · 9%High 16 · 3.6%

12,500 ppm F (NaF/olaflur/dectaflur) amine fluoride gel, professionally applied every 3 months plus home use vs Placebo gel

Number of participants with new demineralised lesions (DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

It is very uncertain whether 12,500 ppm F (NaF/olaflur/dectaflur) amine fluoride gel,… changes number of participants with new demineralised lesions (DLs) compared with 0 ppm F placebo gel (very low certainty).

1 finding from 1 review

Patient-used 250 ppm F mouthrinse (100 ppm amine F/150 ppm NaF), daily vs 0 ppm F placebo mouthrinse, daily

Number of participants with more severe DLs (severity of DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

The review found no eligible studies for this question.

1 finding from 1 review

Slow-release fluoride device (fluoride glass beads) vs Fluoride mouthrinse

Number of participants with new demineralised lesions (DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

It is very uncertain whether intraoral fluoride-releasing glass bead device attached to the brace changes number of participants with new demineralised lesions (DLs) compared with 250 ppm F (daily) fluoride mouthrinse (very low certainty).

1 finding from 1 review

Patient-used 250 ppm F mouthrinse (100 ppm amine F/150 ppm NaF), daily vs 0 ppm F placebo mouthrinse, daily

Number of participants with new demineralised lesions (DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

It is very uncertain whether patient-used 250 ppm F mouthrinse (100 ppm amine F/150 ppm NaF), daily changes number of participants with new demineralised lesions (DLs) compared with 0 ppm F placebo mouthrinse, daily (very low certainty).

1 finding from 1 review

Patient-used 5000 ppm F toothpaste, daily vs 1450 to 1500 ppm F toothpaste

Number of participants with new demineralised lesions (DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

Patient-used 5000 ppm F toothpaste, daily throughout treatment showed no clear difference in number of participants with new demineralised lesions (DLs) compared with 1450 ppm F (conventional) toothpaste, daily (low certainty).

1 finding from 1 review

Professionally-applied 12,300 ppm F APF foam, every 2 months vs 0 ppm F placebo foam

Number of participants with more severe DLs (severity of DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

The review found no eligible studies for this question.

1 finding from 1 review

Professionally-applied 12,300 ppm F APF foam, every 2 months vs 0 ppm F placebo foam

Number of participants with new demineralised lesions (DLs) · Orthodontic patients of any age with fixed braces (new DLs assessed at debond)

Professionally-applied 12,300 ppm F APF foam, every 2 months may leads to lower number of participants with new demineralised lesions (DLs) compared with 0 ppm F placebo foam (low certainty).

1 finding from 1 review

Intervention not reported

Activities of daily living (ADL) (Barthel Index score 0 to 20; lower = 0; median 3‐month · adults with acute stroke

The intervention showed no clear difference in activities of daily living (ADL) (Barthel Index score 0 to 20; lower… (low certainty).

1 finding from 1 review

Intervention not reported

Any complication: participants who experience at least one complication (median 3‐month · adults with acute stroke

The intervention showed no clear difference in any complication: participants who experience at least one… (low certainty).

1 finding from 1 review

Prophylactic oxytocin injection (delivered by community health officer) vs control (no injection)

Early infant death (0‐3 days) [ · pregnant women giving birth in non‐facility settings

Prophylactic oxytocin injection (delivered by community health… showed no clear difference in early infant death (0‐3 days) [ compared with control (no injection) (low certainty).

1 finding from 1 review

Intervention not reported

Late embryo transfer ‐ GM501 (specific) versus Sydney IVF (other) · Women in assisted reproductive technology cycles (ART) receiving human pre‐implantation embryos in either early (cleavage stage transfer)…

It is very uncertain whether the intervention changes late embryo transfer ‐ GM501 (specific) versus Sydney IVF (other) (very low certainty).

1 finding from 1 review

Intervention not reported

Late embryo transfer ‐ G2 (specific) versus Universal IVF (other) · Women in assisted reproductive technology cycles (ART) receiving human pre‐implantation embryos in either early (cleavage stage transfer)…

It is very uncertain whether the intervention changes late embryo transfer ‐ G2 (specific) versus Universal IVF (other) (very low certainty).

1 finding from 1 review

Intervention not reported

Late embryo transfer ‐ ECM/Multiblast (specific) versus Global (other) · Women in assisted reproductive technology cycles (ART) receiving human pre‐implantation embryos in either early (cleavage stage transfer)…

It is very uncertain whether the intervention changes late embryo transfer ‐ ECM/Multiblast (specific) versus Global (other) (very low certainty).

1 finding from 1 review